Novartis is acquiring Cambridge, Massachusetts-based Cadent Therapeutics for $210 million up front and a possible $560 million in milestone payments. Cadent focuses on neuroscience and was launched in 2017 when Luc Therapeutics and Ataxion Therapeutics merged.